IntelGenx Technologies Corp. (IGXT)
USD 0.17
(0.0%)
USD 0.17
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 8.28 Million USD | -9.88% |
| 2022 | 9.19 Million USD | -48.67% |
| 2021 | 17.9 Million USD | 61.05% |
| 2020 | 11.11 Million USD | 0.89% |
| 2019 | 11.02 Million USD | -44.95% |
| 2018 | 20.01 Million USD | 52.26% |
| 2017 | 13.14 Million USD | 2.79% |
| 2016 | 12.79 Million USD | 43.45% |
| 2015 | 8.91 Million USD | 41.88% |
| 2014 | 6.28 Million USD | 1.08% |
| 2013 | 6.21 Million USD | 49.48% |
| 2012 | 4.15 Million USD | -8.99% |
| 2011 | 4.57 Million USD | 150.41% |
| 2010 | 1.82 Million USD | -36.22% |
| 2009 | 2.86 Million USD | 76.47% |
| 2008 | 1.62 Million USD | 27.56% |
| 2007 | 1.27 Million USD | 95.32% |
| 2006 | 650.83 Thousand USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 6.54 Million USD | -20.94% |
| 2023 Q2 | 7.82 Million USD | -24.34% |
| 2023 FY | 8.28 Million USD | -9.88% |
| 2023 Q4 | 8.28 Million USD | 2.08% |
| 2023 Q3 | 8.11 Million USD | 3.69% |
| 2023 Q1 | 10.34 Million USD | 12.52% |
| 2022 Q3 | 11.35 Million USD | -19.98% |
| 2022 Q4 | 9.19 Million USD | -19.06% |
| 2022 Q1 | 18.03 Million USD | 0.73% |
| 2022 Q2 | 14.18 Million USD | -21.33% |
| 2022 FY | 9.19 Million USD | -48.67% |
| 2021 Q2 | 20.41 Million USD | 99.28% |
| 2021 Q4 | 17.9 Million USD | -13.25% |
| 2021 FY | 17.9 Million USD | 61.05% |
| 2021 Q3 | 20.63 Million USD | 1.09% |
| 2021 Q1 | 10.24 Million USD | -7.85% |
| 2020 Q1 | 12.7 Million USD | 15.31% |
| 2020 Q2 | 11.56 Million USD | -8.96% |
| 2020 FY | 11.11 Million USD | 0.89% |
| 2020 Q3 | 10.59 Million USD | -8.43% |
| 2020 Q4 | 11.11 Million USD | 4.96% |
| 2019 FY | 11.02 Million USD | -44.95% |
| 2019 Q4 | 11.02 Million USD | -15.67% |
| 2019 Q3 | 13.06 Million USD | -17.36% |
| 2019 Q2 | 15.81 Million USD | -13.72% |
| 2019 Q1 | 18.32 Million USD | -8.46% |
| 2018 Q2 | 12.09 Million USD | 10.26% |
| 2018 Q3 | 11.04 Million USD | -8.63% |
| 2018 FY | 20.01 Million USD | 52.26% |
| 2018 Q4 | 20.01 Million USD | 81.21% |
| 2018 Q1 | 10.96 Million USD | -16.59% |
| 2017 Q1 | 11.51 Million USD | -9.98% |
| 2017 FY | 13.14 Million USD | 2.79% |
| 2017 Q4 | 13.14 Million USD | -13.31% |
| 2017 Q3 | 15.16 Million USD | 43.56% |
| 2017 Q2 | 10.56 Million USD | -8.24% |
| 2016 FY | 12.79 Million USD | 43.45% |
| 2016 Q4 | 12.79 Million USD | -5.07% |
| 2016 Q3 | 13.47 Million USD | 54.24% |
| 2016 Q2 | 8.73 Million USD | 10.04% |
| 2016 Q1 | 7.93 Million USD | -10.97% |
| 2015 Q1 | 5.71 Million USD | -9.1% |
| 2015 Q3 | 7.09 Million USD | 27.5% |
| 2015 FY | 8.91 Million USD | 41.88% |
| 2015 Q2 | 5.56 Million USD | -2.64% |
| 2015 Q4 | 8.91 Million USD | 25.75% |
| 2014 FY | 6.28 Million USD | 1.08% |
| 2014 Q3 | 5.59 Million USD | -11.81% |
| 2014 Q2 | 6.34 Million USD | 0.65% |
| 2014 Q1 | 6.3 Million USD | 1.38% |
| 2014 Q4 | 6.28 Million USD | 12.31% |
| 2013 Q1 | 3.21 Million USD | -22.72% |
| 2013 FY | 6.21 Million USD | 49.48% |
| 2013 Q4 | 6.21 Million USD | 66.45% |
| 2013 Q3 | 3.73 Million USD | 3.46% |
| 2013 Q2 | 3.61 Million USD | 12.32% |
| 2012 Q1 | 5.05 Million USD | 10.66% |
| 2012 FY | 4.15 Million USD | -8.99% |
| 2012 Q4 | 4.15 Million USD | 10.85% |
| 2012 Q3 | 3.75 Million USD | -11.82% |
| 2012 Q2 | 4.25 Million USD | -15.86% |
| 2011 Q1 | 1.31 Million USD | -28.0% |
| 2011 Q2 | 3.77 Million USD | 187.6% |
| 2011 Q3 | 3.89 Million USD | 3.02% |
| 2011 Q4 | 4.57 Million USD | 17.39% |
| 2011 FY | 4.57 Million USD | 150.41% |
| 2010 Q1 | 2.41 Million USD | -15.6% |
| 2010 FY | 1.82 Million USD | -36.22% |
| 2010 Q3 | 2.73 Million USD | 80.0% |
| 2010 Q2 | 1.52 Million USD | -37.06% |
| 2010 Q4 | 1.82 Million USD | -33.3% |
| 2009 Q3 | 3.45 Million USD | 187.33% |
| 2009 Q2 | 1.2 Million USD | -0.77% |
| 2009 Q4 | 2.86 Million USD | -17.18% |
| 2009 Q1 | 1.21 Million USD | -25.27% |
| 2009 FY | 2.86 Million USD | 76.47% |
| 2008 Q2 | 2.82 Million USD | -22.26% |
| 2008 Q4 | 1.62 Million USD | -26.94% |
| 2008 Q3 | 2.21 Million USD | -21.38% |
| 2008 Q1 | 3.63 Million USD | 185.66% |
| 2008 FY | 1.62 Million USD | 27.56% |
| 2007 Q2 | 1.89 Million USD | 271.63% |
| 2007 Q4 | 1.27 Million USD | -15.48% |
| 2007 Q1 | 510.21 Thousand USD | -21.61% |
| 2007 FY | 1.27 Million USD | 95.32% |
| 2007 Q3 | 1.5 Million USD | -20.68% |
| 2006 Q2 | 1.15 Million USD | 0.0% |
| 2006 Q4 | 650.83 Thousand USD | -31.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | 650.83 Thousand USD | 0.0% |
| 2006 Q3 | 943.18 Thousand USD | -18.36% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| HST Global, Inc. | 1526.00 USD | -542626.081% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2242.082% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -3068.761% |
| CytoDyn Inc. | 11.13 Million USD | 25.629% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 93.555% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| MultiCell Technologies, Inc. | 126.22 USD | -6561459.182% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -1922.852% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -322.942% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -201.566% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -14405.903% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | 2.45 Million USD | -237.742% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 70.362% |
| SQZ Biotechnologies Company | 107.18 Million USD | 92.273% |
| Resverlogix Corp. | 8.11 Million USD | -2.058% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -974.686% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -509.709% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -2473.6% |
| Mesoblast Limited | 667.9 Million USD | 98.76% |
| GB Sciences, Inc. | 103.44 Thousand USD | -7906.419% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2242.082% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 21.527% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 7.455% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 72.407% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -341.029% |
| ContraFect Corporation | 20.67 Million USD | 59.95% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -99.758% |
| BioStem Technologies, Inc. | 14.56 Million USD | 43.119% |
| LadRx Corporation | 2.3 Million USD | -258.857% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -1104.679% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -7713.208% |
| CSL Limited | 38.02 Billion USD | 99.978% |
| Biomind Labs Inc. | 73.81 Thousand USD | -11119.334% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -1559.59% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 93.64% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -1400.036% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 78.68% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -14.713% |
| GeneThera, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 76.458% |
| Adynxx, Inc. | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -11344.759% |
| Marizyme, Inc. | 22.01 Million USD | 62.38% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -1220.893% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -2048.54% |
| Zenith Capital Corp. | 7410.00 USD | -111667.881% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -478.339% |
| Halberd Corporation | 10.13 Thousand USD | -81649.087% |
| Genus plc | 1.02 Billion USD | 99.195% |
| Pharming Group N.V. | 462.85 Million USD | 98.211% |
| MetaStat, Inc. | - USD | -Infinity% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -149.984% |
| IMV Inc. | 31.33 Million USD | 73.568% |
| Affymax, Inc. | 7.44 Million USD | -11.272% |
| SYBLEU INC | 330.46 Thousand USD | -2406.143% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 82.638% |
| Enzolytics Inc. | 361.7 Million USD | 97.71% |
| argenx SE | 4.54 Billion USD | 99.818% |
| AVAX Technologies, Inc. | 7.37 Million USD | -12.265% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -2067.059% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -358428.139% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -781.355% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -5692.743% |
| Cell Source, Inc. | 195.17 Thousand USD | -4143.458% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -1818.4% |
| Q BioMed Inc. | 3.51 Million USD | -135.584% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -8558.018% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 84.285% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -3069.816% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -2021.599% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 98.144% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -471.629% |
| Rebus Holdings, Inc. | 5000.00 USD | -165540.0% |
| Helix BioMedix, Inc. | 3.02 Million USD | -173.777% |
| Skye Bioscience, Inc. | 11.94 Million USD | 30.639% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -792.494% |
| ONE Bio Corp. | 70.08 Million USD | 88.183% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -218.147% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -738.287% |
| Agentix Corp. | 261.39 Thousand USD | -3068.421% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -1194.758% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -36254.857% |
| Ember Therapeutics, Inc. | 184.00 USD | -4500986.957% |
| Kadimastem Ltd | 2.3 Million USD | -259.449% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -10746.845% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -1623.417% |
| NovAccess Global Inc. | 62.24 Thousand USD | -13204.845% |
| Itoco Inc. | 1.4 Million USD | -491.541% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -46219.911% |
| Qrons Inc. | 420.00 USD | -1971804.762% |
| Mobile Lads Corp. | 52.00 USD | -15926823.077% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.755% |
| International Stem Cell Corporation | 5.39 Million USD | -53.655% |
| Bioxytran, Inc. | 137.63 Thousand USD | -5917.234% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 44.793% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 50.045% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -10383.544% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -857.814% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -10.177% |
| Neutra Corp. | 2851.00 USD | -290394.563% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 74.443% |
| PureTech Health plc | 693.97 Million USD | 98.807% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -2.613% |
| IXICO plc | 15.84 Million USD | 47.728% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 91.984% |
| CSL Limited | 38.02 Billion USD | 99.978% |
| Cellectis S.A. | 333.99 Million USD | 97.52% |